[HTML] europepmc.org

[HTML][HTML] Clopidogrel therapy and CYP2C19 genotype

2018 - europepmc.org
Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …
被引用次数：87 相关文章

Clopidogrel Therapy and CYP2C19 Genotype

L Dean, M Kane - Medical Genetics Summaries [Internet], 2012 - pubmed.ncbi.nlm.nih.gov
Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …
[HTML] europepmc.org

[HTML][HTML] Clopidogrel Therapy and CYP2C19 Genotype

L Dean, M Kane - 2018 - europepmc.org
Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …
[HTML] nih.gov

[HTML][HTML] Clopidogrel Therapy and CYP2C19 Genotype

L Dean, M Kane - Medical Genetics Summaries [Internet], 2022 - ncbi.nlm.nih.gov
Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …
[HTML] nih.gov

[HTML][HTML] Clopidogrel Therapy and CYP2C19 Genotype

L Dean, M Kane - Medical Genetics Summaries [Internet], 2022 - ncbi.nlm.nih.gov
Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of
myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS) …